Input virion proteins: Cryptic targets of antivector immune responses in preimmunized subjects

Molecular Therapy

Volumn 9, Issue 6, 2004, Pages 771-774

  Lowenstein, Pedro R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PROTEIN; TOLL LIKE RECEPTOR; VIRUS VECTOR;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CELLULAR IMMUNITY; DRUG TARGETING; GENE EXPRESSION; GENETIC CODE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREGULATION; NONHUMAN; NOTE; REGULATOR GENE; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HUMANS; IMMUNIZATION; VIRAL PROTEINS; VIRION;

ADENOVIRIDAE; LENTIVIRUS; PARVOVIRUS;

EID: 3042856167     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.05.019     Document Type: Note

References (25)

1. Lowenstein, P. R. (2003). Immune responses to viral vectors. Gene Ther. 10: 933-998.
2. Thomas, C. E. et al. (2001). Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 12: 839-46.
3. Maione, D. et al. (2001). An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. 98: 5986-91.
4. Sanftner, L. M. et al. (2004). Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol. Ther. 9: 403-9.
5. Peden, C., Burger, C., Muzyczka, N., and Mandel, R. J. (2003). The effects of preimmunization to wtAAV on single and multiple administrations of rAAV in the brain. Mol. Ther. 7: S312.
6. Peden, C., Burger, C., Muzyczka, N., and Mandel, R. J. (2004). Circulating anti-wt-AAV2 antibodies inhibit rAAV2-, but not rAAV5-mediated gene transfer in the brain. J. Virol. In Press.
7. Medzhitov, R. and Janeway, C. A., Jr. (1997). Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-8.
8. Smith, A. E. and Helenius, A. (2004). How viruses enter animal cells. Science 304: 237-42.
9. Greber, U. F. (2002). Signalling in viral entry. Cell Mol. Life Sci. 59: 608-26.
10. Kafri, T. et al. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. 95: 11377-82.
11. Thomas, C. E., Storm, T. A., Huang, Z. and Kay, M. A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adenoassociated virus vectors. J. Virol. 78: 3110-22.
12. Sabatino, D. et al. (2003). An animal model of transient transaminitis and diminished factor IX expression following AAV-mediated liver-directed gene transfer for hemophilia B. Blood. 102: 493a.
13. Lowenstein, P. R. and Castro, M. G. (2003). Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther. 10: 946-54.
14. Molinier-Frenkel, V. et al. (2000). Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J. Virol. 74: 7678-82.
15. Halbert, C. L. et al. (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74: 1524-32.
16. Bramson, J. L., Hitt, M., Gauldie, J. and Graham, F. L. (1997). Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4: 1069-76.
17. Brockman, M. A. and Knipe, D. M. (2002). Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. Virol. 76: 3678-87.
18. Greber, U. F., Webster, P., Weber, J. and Helenius, A. (1996). The role of the adenovirus protease on virus entry into cells. Embo J. 15: 1766-77.
19. Thomas, C. E. et al. (2000). Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. 97: 7482-7.
20. Yang, Y., Ertl, H. C. and Wilson, J. M. (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1: 433-42.
21. Wadsworth, S. C., Zhou, H., Smith, A. E. and Kaplan, J. M. (1997). Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol. 71: 5189-96.
22. Yewdell, J. W. and Hill, A. B. (2002). Viral interference with antigen presentation. Nat. Immunol. 3: 1019-25.
23. Duan, D. et al. (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105: 1573-87.
24. Yan, Z. et al. (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76: 2043-53.
25. Yan, Z. et al. (2004). Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithlea. J. Virol. 78: 2863-74.